We recently observed a patient in whom we suspected an interaction of azapropazone with phenytoin resulting in phenytoin toxicity. This and a report of a similar case' led us to investigate the effect of azapropazone on steady-state plasma phenytoin concentrations in five healthy volunteers.
Interaction of azapropazone with phenytoin
We recently observed a patient in whom we suspected an interaction of azapropazone with phenytoin resulting in phenytoin toxicity. This and a report of a similar case' led us to investigate the effect of azapropazone on steady-state plasma phenytoin concentrations in five healthy volunteers.
Subjects and results

INITIAL CASE
A 60-year-old man who had had grand mal epilepsy for three years was receiving maintenance treatment of phenytoin 300 mg daily. rose to 27 JLmol/l (6&7 itg/ml) and then fell to 10 jLmol/l (2-5 jLg/ml).
Comment
Azapropazone added during steady-state administration of phenytoin doubled plasma phenytoin concentrations. The initial fall in phenytoin concentrations when azapropazone was added, followed by a gradual rise, resembled the results of Neuvonen et al,3 who observed similar changes in epileptic patients starting phenylbutazone, a pyrazolidine derivative related to azapropazone. Phenytoin is 90% and azapropazone 95% plasma protein bound, and probably azapropazone displaces phenytoin from protein-binding sites, leading to an increase in the free fraction of phenytoin in the plasma and an increase in the rate of clearance of total phenytoin with a decrease in plasma total phenytoin concentration. The reverse would happen on withdrawal of azapropazone (see figure) .
The subsequent rise in plasma phenytoin concentrations was probably due to decreased clearance of phenytoin. Metabolism of phenytoin is the main mechanism of clearance of the drug, and there is good evidence that some drugs-for example, chloramphenicol and isoniazid-inhibit metabolism of phenytoin.4 Azapropazone decreases the rate of clearance, and therefore presumably inhibits the metabolism, of tolbutamide.5 An effect on absorption of phenytoin is unlikely since phenytoin (Epanutin) is almost completely absorbed. We cannot rule out altered tissue distribution occurring during this interaction, but that alone would not account for the changes in steady-state plasma phenytoin concentrations during azapropazone treatment.
We used doses of phenytoin that produced initial plasma phenytoin concentrations well below the therapeutic range (40-80 ,umol/l; 10-20 pg/ml). The concentrations doubled during azapropazone treatment, and even greater changes might be expected in patients starting with concentrations within the therapeutic range because of the non-linearity of phenytoin pharmacokinetics. This is therefore a potentially dangerous interaction. We advise avoiding azapropazone in patients treated with phenytoin.
The Committee on Safety of Medicines and the drug's manufacturer know of only one case of interaction between azapropazone and phenytoin.'
